Premium
(−)−Epigallocatechin‐3‐gallate Inhibits Pancreatic Lipase and Reduces Body Weight Gain in High Fat‐Fed Obese Mice
Author(s) -
Grove Kimberly A.,
SaeTan Sudathip,
Kennett Mary J.,
Lambert Joshua D.
Publication year - 2012
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1038/oby.2011.139
Subject(s) - epigallocatechin gallate , endocrinology , medicine , weight gain , obesity , lipase , chemistry , weight loss , body weight , diet induced obese , enzyme , polyphenol , biochemistry , insulin resistance , antioxidant
Tea ( Camellia sinensis , Theaceae) has been shown to have obesity preventive effects in laboratory studies. We hypothesized that dietary epigallocatechin‐3‐gallate (EGCG) could reverse metabolic syndrome in high fat‐fed obese C57bl/6J mice, and that these effects were related to inhibition of pancreatic lipase (PL). Following treatment with 0.32% EGCG for 6 weeks, a 44% decrease in body weight (BW) gain in high fat‐fed, obese mice ( P < 0.01) was observed compared to controls. EGCG treatment increased fecal lipid content by 29.4% ( P < 0.05) compared to high fat‐fed control, whereas in vitro , EGCG dose‐dependently inhibited PL (IC 50 = 7.5 µmol/l) in a noncompetitive manner with respect to substrate concentration. (−)−Epicatechin‐3‐gallate exhibited similar inhibitory activity, whereas the nonester‐containing (−)−epigallocatechin did not. In conclusion, EGCG supplementation reduced final BW and BW gain in obese mice, and some of these effects may be due to inhibition of PL by EGCG.